Friday May 24, 2013 0 commentsFORT COLLINS - CHD Bioscience announced it has been awarded a second U.S. patent (U.S. No. 8,445,717) related to the development of its family of novel antimicrobial compounds.
"This patent covers the composition of matter for additional antimicrobial compounds that are in the same class as our lead product candidate, VERIOX," said Ed Neas, CHD's CTO. "We believe the addition of these compounds furthers our mission to effectively address current and future infectious diseases within the world."
"I am very pleased with the state of CHD's intellectual property and I am looking forward to the continued growth of our patent portfolio," added Michael K. Handley, CHD's CEO.
CHD, a development stage life science company, is working to commercialize a new class of antimicrobial products that have demonstrated -- both in vitro and in vivo -- the ability to safely eliminate a broad range of bacteria, viruses and other pathogens without harming human tissue. CHD said its technology has demonstrated the ability to quickly kill even the most resistant pathogens, such as MRSA and C. difficile.
CHD's first product, trade-marked and brand-named VERIOX, is being developed for a wide variety of markets including skin surface disinfection, medical device coatings and advanced wound care applications worldwide.
CHD said it is developing novel antimicrobial products that can mitigate or treat the increasing threat of Hospital Acquired Infections. The Fort Collins-based company is located in the Research Innovation Center on the Colorado State University Foothills Campus.
For more information, visit www.chdbioscience.com. The company said inquiries may be directed to [email protected].